EUVIMEDScopri EUVIMED
Open access · CC BY-NC-ND 4.0

Influence of Peptide‐Based Chelator Sequences on HER2‐Targeting Radiopeptide

Sonal Gupta, Manoj Kumar, Krishna Mohan Repaka, Amit Das iD, Ajit A Kengar, Drishty Satpati iD

Journal of Peptide Science · 2026-05 · 32 (5)

DOI: 10.1002/psc.70094 ↗

At a glance

Journal article in Journal of Peptide Science, published online on 2026-03-19. Written by Sonal Gupta and 5 co-authors. Institution: Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India. Major MEDLINE topics: Erb-b2 Receptor Tyrosine Kinases, Chelating Agents, Peptides, Breast Neoplasms. 24 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

In our pursuit of developing HER2‐targeting radiolabeled peptides for detection and therapy of HER2‐positive breast cancer, the previously reported rL‐A9 peptide had shown promising potential. In the present work, a different variant of rL‐A9 was designed by incorporation of peptide‐based chelators for 99m Tc‐labeling. Cysteine‐based amino acids (CGGG, CSSG, CEEG) were conjugated at the N‐terminus of the peptide and were radiolabeled with [ 99m Tc]NaTcO 4 . Of the three radiopeptides, [ 99m Tc]Tc‐CGGG‐rL‐A9 exhibited high stability, whereas [ 99m Tc]Tc‐CSSG‐rL‐A9 and [ 99m Tc]Tc‐CEEG‐rL‐A9 decomposed rapidly. Hence, only CGGG‐incorporated radiopeptide was further investigated in vitro in human breast carcinoma SKBR3 cells and in vivo in tumor xenografted mice. Cell‐binding studies demonstrated high binding affinity [K d : 5.82 ± 0.92 nM] and specificity (63% reduction in blocking study) of [ 99m Tc]Tc‐CGGG‐rL‐A9 toward HER2‐expressing cells. In vivo studies showed moderate tumor uptake (3.56 ± 0.81% ID/g, 1 h) with 82.8% retention at 3 h (3.16 ± 0.22% ID/g). Moderately high tumor‐to‐background ratios, along with washout from the other non‐target organs, were observed. Inhibition studies revealed 52.6% reduction in the tumor activity, signifying high HER2‐receptor specificity of the presently studied radiopeptide, [ 99m Tc]Tc‐CGGG‐rL‐A9.

Subjects

MeSH terms (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesChelating AgentsPeptidesBreast NeoplasmsRadiopharmaceuticalsOrganotechnetium CompoundsHumansAnimalsFemaleMiceTechnetiumCell Line, TumorTissue DistributionMice, NudeAmino Acid Sequence

Author keywords

HER2 receptorspeptide‐based chelatorsrL‐A9technetium‐99 m

Substances

Erb-b2 Receptor Tyrosine KinasesChelating AgentsPeptidesTechnetiumRadiopharmaceuticalsERBB2 protein, humanOrganotechnetium Compounds

Authors and institutions

  • Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India.
  • KET'S V. G. Vaze College, Mumbai University, Mumbai, India.
  • Board of Radiation and Isotope Technology, Mumbai, India.
  • Protein Crystallography Section, Bio-Science Group, Bhabha Atomic Research Centre, Mumbai, India.
  • Homi Bhabha National Institute, Mumbai, India.

ORCID profiles: Amit Das, Drishty Satpati

Cite

APA

Gupta, S., Kumar, M., Repaka, K. M., Das, A., Kengar, A. A., & Satpati, D. (2026). Influence of Peptide‐Based Chelator Sequences on HER2‐Targeting Radiopeptide. Journal of Peptide Science, 32(5). https://doi.org/10.1002/psc.70094

Vancouver

Gupta S, Kumar M, Repaka KM, Das A, Kengar AA, Satpati D. Influence of Peptide‐Based Chelator Sequences on HER2‐Targeting Radiopeptide. Journal of Peptide Science. 2026;32(5). doi:10.1002/psc.70094

BibTeX
@article{Gupta2026,
  author = {Gupta, Sonal and Kumar, Manoj and Repaka, Krishna Mohan and Das, Amit and Kengar, Ajit A and Satpati, Drishty},
  title = {Influence of Peptide‐Based Chelator Sequences on HER2‐Targeting Radiopeptide},
  journal = {Journal of Peptide Science},
  year = {2026},
  volume = {32},
  number = {5},
  doi = {10.1002/psc.70094}
}
Start for free →